At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
In Brief
A Phase 2 clinical trial evaluating Tepotinib and Osimertinib for Non-small Cell Lung Cancer. Active but no longer recruiting, targeting 140 participants across 179 sites in 17 countries.
Detailed Summary
This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Study Details
Timeline
Interventions
Participants were administered with Tepotinib orally once daily at a dose of 500 mg.
Participants received Osimertinib at a dose of 80 mg orally once daily.